TLC to Present at Upcoming Conferences
22 avr. 2019 04h00 HE
|
TLC
SOUTH SAN FRANCISCO, CA and TAIPEI, Taiwan, April 22, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and...
TLC Announces Positive End-of-Phase II Meeting with FDA for TLC599 in Knee Osteoarthritis
15 avr. 2019 05h00 HE
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, April 15, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and...
TLC Announces Full Enrollment in Part 1 of Phase II Trial of TLC590 for Postsurgical Pain Management following Bunionectomy
08 avr. 2019 05h00 HE
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, April 08, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and...
TLC Reports Fourth Quarter and Full Year 2018 Financial Results and Business Update
01 avr. 2019 05h00 HE
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, April 01, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and...
TLC to Present High-Scoring Scientific Abstracts on Acute Pain through Moderated Sessions at ASRA Spring 2019
25 mars 2019 05h00 HE
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPAI, Taiwan, March 25, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and...
TLC Announces First Patient Dosed in Phase II Trial of TLC590 for Postsurgical Pain Management following Bunionectomy
18 mars 2019 05h00 HE
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, March 18, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and...
TLC Reports Positive Top-Line Results from Phase I/II Clinical Trial of TLC590 for Postsurgical Pain
11 mars 2019 06h27 HE
|
Taiwan Liposome Company, Ltd.
TAIPEI, Taiwan and SOUTH SAN FRANCISCO, Calif., March 11, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and...
TLC and 3SBio Form Exclusive Partnership to Commercialize Two NanoX™ Products in Mainland China
03 mars 2019 21h57 HE
|
Taiwan Liposome Company, Ltd.
SOUTH SAN FRANCISCO, Calif., TAIWAN, SHEN YANG, China and HONG KONG, March 04, 2019 (GLOBE NEWSWIRE) -- Taiwan Liposome Company, Ltd. (“TLC”)(Nasdaq: TLC, TWO: 4152), a clinical-stage specialty...
TLC Appoints George Spencer-Green, MD, MS, as Chief Medical Officer
25 janv. 2019 03h53 HE
|
Taiwan Liposome Company, Ltd.
TAIPEI, Taiwan and SOUTH SAN FRANCISCO, Calif., Jan. 25, 2019 (GLOBE NEWSWIRE) -- Taiwan Liposome Company, Ltd. (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated...
EMA Grants Orphan Drug Designation to TLC178 for the Treatment of Soft Tissue Sarcoma
22 janv. 2019 06h00 HE
|
Taiwan Liposome Company, Ltd.
TAIPEI, Taiwan and SOUTH SAN FRANCISCO, Calif., Jan. 22, 2019 (GLOBE NEWSWIRE) -- Taiwan Liposome Company, Ltd. (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated...